S&P 500   4,554.57 (+0.09%)
DOW   35,701.12 (+0.76%)
QQQ   387.55 (-0.58%)
AAPL   188.84 (-0.28%)
MSFT   377.59 (-0.33%)
META   328.57 (-1.09%)
GOOGL   133.63 (-1.01%)
AMZN   145.79 (-0.36%)
TSLA   240.89 (-1.33%)
NVDA   474.37 (-1.46%)
NIO   7.26 (+1.11%)
BABA   74.17 (-0.67%)
AMD   121.83 (-1.63%)
T   16.48 (+1.10%)
F   10.46 (-1.23%)
MU   75.74 (-1.24%)
CGC   0.56 (-0.82%)
GE   119.45 (+0.50%)
DIS   92.75 (+0.27%)
AMC   6.90 (-3.77%)
PFE   30.01 (-0.23%)
PYPL   57.37 (-1.04%)
XOM   104.10 (+1.72%)
S&P 500   4,554.57 (+0.09%)
DOW   35,701.12 (+0.76%)
QQQ   387.55 (-0.58%)
AAPL   188.84 (-0.28%)
MSFT   377.59 (-0.33%)
META   328.57 (-1.09%)
GOOGL   133.63 (-1.01%)
AMZN   145.79 (-0.36%)
TSLA   240.89 (-1.33%)
NVDA   474.37 (-1.46%)
NIO   7.26 (+1.11%)
BABA   74.17 (-0.67%)
AMD   121.83 (-1.63%)
T   16.48 (+1.10%)
F   10.46 (-1.23%)
MU   75.74 (-1.24%)
CGC   0.56 (-0.82%)
GE   119.45 (+0.50%)
DIS   92.75 (+0.27%)
AMC   6.90 (-3.77%)
PFE   30.01 (-0.23%)
PYPL   57.37 (-1.04%)
XOM   104.10 (+1.72%)
S&P 500   4,554.57 (+0.09%)
DOW   35,701.12 (+0.76%)
QQQ   387.55 (-0.58%)
AAPL   188.84 (-0.28%)
MSFT   377.59 (-0.33%)
META   328.57 (-1.09%)
GOOGL   133.63 (-1.01%)
AMZN   145.79 (-0.36%)
TSLA   240.89 (-1.33%)
NVDA   474.37 (-1.46%)
NIO   7.26 (+1.11%)
BABA   74.17 (-0.67%)
AMD   121.83 (-1.63%)
T   16.48 (+1.10%)
F   10.46 (-1.23%)
MU   75.74 (-1.24%)
CGC   0.56 (-0.82%)
GE   119.45 (+0.50%)
DIS   92.75 (+0.27%)
AMC   6.90 (-3.77%)
PFE   30.01 (-0.23%)
PYPL   57.37 (-1.04%)
XOM   104.10 (+1.72%)
S&P 500   4,554.57 (+0.09%)
DOW   35,701.12 (+0.76%)
QQQ   387.55 (-0.58%)
AAPL   188.84 (-0.28%)
MSFT   377.59 (-0.33%)
META   328.57 (-1.09%)
GOOGL   133.63 (-1.01%)
AMZN   145.79 (-0.36%)
TSLA   240.89 (-1.33%)
NVDA   474.37 (-1.46%)
NIO   7.26 (+1.11%)
BABA   74.17 (-0.67%)
AMD   121.83 (-1.63%)
T   16.48 (+1.10%)
F   10.46 (-1.23%)
MU   75.74 (-1.24%)
CGC   0.56 (-0.82%)
GE   119.45 (+0.50%)
DIS   92.75 (+0.27%)
AMC   6.90 (-3.77%)
PFE   30.01 (-0.23%)
PYPL   57.37 (-1.04%)
XOM   104.10 (+1.72%)

Regeneron Pharmaceuticals Stock Price, News & Analysis (NASDAQ:REGN)

$817.56
+8.97 (+1.11%)
(As of 10:02 AM ET)
Compare
Today's Range
$810.25
$818.41
50-Day Range
$775.18
$843.66
52-Week Range
$668.00
$853.97
Volume
34,097 shs
Average Volume
558,034 shs
Market Capitalization
$89.07 billion
P/E Ratio
23.32
Dividend Yield
N/A
Price Target
$903.52

Regeneron Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.69 Rating Score
Upside/​Downside
11.7% Upside
$903.52 Price Target
Short Interest
Healthy
1.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.69
Upright™ Environmental Score
News Sentiment
1.05mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$2.58 M Sold Last Quarter
Proj. Earnings Growth
2.11%
From $35.55 to $36.30 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

134th out of 949 stocks

Pharmaceutical Preparations Industry

47th out of 445 stocks


REGN stock logo

About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Stock Price History

REGN Stock News Headlines

Why Microsoft Just Placed A Huge Bet On Nuclear
Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.
11 Analysts Have This to Say About Regeneron Pharmaceuticals
Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How
Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?
Why Microsoft Just Placed A Huge Bet On Nuclear
Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.
Regeneron Announces Investor Conference Presentation
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/02/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
11,851
Year Founded
1988

Price Target and Rating

Average Stock Price Target
$903.52
High Stock Price Target
$1,050.00
Low Stock Price Target
$680.00
Potential Upside/Downside
+11.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
26 Analysts

Profitability

Net Income
$4.34 billion
Pretax Margin
33.42%

Debt

Sales & Book Value

Annual Sales
$12.17 billion
Cash Flow
$45.12 per share
Book Value
$228.59 per share

Miscellaneous

Free Float
99,327,000
Market Cap
$88.10 billion
Optionable
Optionable
Beta
0.13

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Regeneron Pharmaceuticals was last updated on Tuesday, November 28, 2023 at 10:48 PM.

Pros

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

  • Regeneron Pharmaceuticals, Inc. is a global company that discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
  • Regeneron Pharmaceuticals, Inc. has a strong track record of successful research and development, with a focus on innovative treatments and therapies.
  • Recent developments in Regeneron Pharmaceuticals, Inc.'s pipeline show promising potential for new drugs and treatments.
  • Regeneron Pharmaceuticals, Inc. has established partnerships with reputable organizations, such as the U.S. Biomedical Advanced Research Development Authority and AstraZeneca PLC.
  • Investing in Regeneron Pharmaceuticals, Inc. provides an opportunity to support advancements in medical science and contribute to improving healthcare worldwide.

Cons

Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

  • The stock price of Regeneron Pharmaceuticals, Inc. is subject to market fluctuations and may not always reflect the company's true value.
  • As with any pharmaceutical company, there are risks associated with the success of drug development and regulatory approvals.
  • Competition in the pharmaceutical industry is intense, and Regeneron Pharmaceuticals, Inc. may face challenges from other companies with similar products or treatments.
  • Changes in healthcare policies and regulations can impact the profitability and market demand for Regeneron Pharmaceuticals, Inc.'s products.
  • Investing in the pharmaceutical industry requires careful consideration of the potential risks and rewards, as well as a long-term investment perspective.














REGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price target for 2024?

26 equities research analysts have issued 12-month target prices for Regeneron Pharmaceuticals' stock. Their REGN share price targets range from $680.00 to $1,050.00. On average, they expect the company's share price to reach $903.52 in the next year. This suggests a possible upside of 11.7% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2023?

Regeneron Pharmaceuticals' stock was trading at $721.49 on January 1st, 2023. Since then, REGN shares have increased by 12.1% and is now trading at $808.59.
View the best growth stocks for 2023 here
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 2nd 2024.
View our REGN earnings forecast
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings data on Thursday, November, 2nd. The biopharmaceutical company reported $10.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.39 by $0.78. The biopharmaceutical company had revenue of $3.36 billion for the quarter, compared to analyst estimates of $3.23 billion. Regeneron Pharmaceuticals had a net margin of 30.47% and a trailing twelve-month return on equity of 18.61%. Regeneron Pharmaceuticals's revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $9.98 EPS.
Read the conference call transcript
.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (9.03%), Loomis Sayles & Co. L P (1.14%), Northern Trust Corp (0.98%), Morgan Stanley (0.89%), Bank of New York Mellon Corp (0.89%) and Legal & General Group Plc (0.75%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
This page (NASDAQ:REGN) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -